| ASTX727 (oral cedazuridine + decitabine) |
biorxiv |
cedazuridine decitabine oral hypomethylating myeloproliferative neoplasm |
Targets the oral cedazuridine+decitabine combination (ASTX727) specifically in MPN context, distinct from the existing 'decitabine cedazuridine venetoclax CMML' query by omitting venetoclax/BCL-2 and broadening to MPN applications including iadademstat combinations. |
manually-archived |
| ASTX727 (oral cedazuridine + decitabine) |
pubmed |
("ASTX727"[Title/Abstract] OR "cedazuridine"[Title/Abstract] OR "oral decitabine"[Title/Abstract]) AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract] OR "MPN"[Title/Abstract] OR "MDS/MPN"[Title/Abstract]) AND ("iadademstat"[Title/Abstract] OR "LSD1"[Title/Abstract] OR "decitabine"[Title/Abstract]) |
Targets ASTX727/cedazuridine in MPN contexts beyond the existing venetoclax+CMML query, capturing the iadademstat combination trial and broader MPN/MDS-MPN decitabine oral formulation studies not covered by existing queries. |
demoted |
| Selinexor + Ruxolitinib combination |
biorxiv |
selinexor ruxolitinib combination myelofibrosis XPO1 JAK inhibitor |
Targets the specific combination therapy of selinexor plus ruxolitinib in myelofibrosis, which is not covered by existing queries that treat selinexor (XPO1) and ruxolitinib as separate topics. |
manually-archived |
| Selinexor + Ruxolitinib combination |
pubmed |
"selinexor"[Title/Abstract] AND "ruxolitinib"[Title/Abstract] AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) |
The existing XPO1/selinexor query covers selinexor broadly in MPNs, but this query specifically targets the selinexor+ruxolitinib combination, which is the precise focus of this concept page and not captured by any existing query. |
active |
| XPO1 nuclear export |
biorxiv |
XPO1 exportin-1 nuclear export selinexor myeloproliferative neoplasm myelofibrosis |
No existing query targets XPO1/exportin-1 inhibition or selinexor in the MPN context; this directly captures mechanistic and clinical preprints on nuclear export blockade in myeloproliferative neoplasms. |
manually-archived |
| XPO1 nuclear export |
pubmed |
"XPO1"[Title/Abstract] AND ("selinexor"[Title/Abstract] OR "nuclear export"[Title/Abstract] OR "exportin"[Title/Abstract]) AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract] OR "polycythemia vera"[Title/Abstract]) |
Targets XPO1/exportin-1 nuclear export inhibition in MPN contexts directly, which no existing query covers—selinexor appears only in the static page findings and is not captured by any current dynamic query. |
demoted |
| Thrombosis risk |
biorxiv |
thrombosis polycythemia vera essential thrombocythemia hematocrit platelet JAK2 V617F risk |
Targets thrombotic risk mechanisms specific to PV/ET (hematocrit, platelet activation, JAK2 V617F allele burden) on biorxiv, which no existing query covers. |
manually-archived |
| Thrombosis risk |
pubmed |
("thrombosis"[Title/Abstract] OR "thromboembolic"[Title/Abstract]) AND ("hematocrit"[Title/Abstract] OR "leukocytosis"[Title/Abstract] OR "platelet activation"[Title/Abstract] OR "allele burden"[Title/Abstract]) AND ("polycythemia vera"[Title/Abstract] OR "essential thrombocythemia"[Title/Abstract] OR "myeloproliferative"[Title/Abstract]) |
Targets the mechanistic drivers of thrombosis risk (hematocrit, leukocytosis, platelet activation, allele burden) in MPN specifically, which no existing query captures together. |
active |